Story thread · 2 reports / 2 sources
FDA Grants Priority Review to Zasocitinib for Psoriasis
medscape.com · 4h
How the coverage leans
Across 2 sources · syndicated copies counted once
Zasocitinib is also being evaluated in phase 3 studies for psoriatic arthritis and in phase 2 studies for Crohn’s disease, ulcerative colitis, vitiligo, and hidradenitis suppurativa. Medscape Medical News
First report: U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations — financialpost.com, 2d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.